Here’s our latest roundup of news from San Diego’s life sciences community.
—It took awhile, but San Diego’s Pathway Genomics appears to have recovered from the ill effects of a 2010 letter from the FDA that more or less brought its business to a halt. Under a revised strategy, the company has been forming partnerships to provide physicians and their patients with genetic reports that screen for an individual’s response to prescribed drugs, propensity for complex disease, and other genetic conditions. This week, Pathway Genomics said its latest partnership is with the exclusive Scripps Center for Executive Health in La Jolla. That market demographic is quite a contrast from Pathway Genomics’ plan in 2010 to sell a personal genome test kit through Walgreens stores.
—San Diego’s Optimer Pharmaceuticals (Nasdaq: OPTR) said it is selling its remaining stake in Optimer Biotechnology, its Taiwanese affiliate, for $60 million. In April, Optimer Pharmaceuticals ousted Michael Chang, its chairman and a co-founder, and fired the CFO, and another executive, citing compliance and conflict-of-interest issues related to Optimer Biotechnology shares awarded to Chang. Optimer said proceeds from its 43 percent stake would be used to fund marketing of fidaxomicin (Dificid), its antibacterial drug for Clostridium difficile-associated diarrhea.
—CareFusion (NYSE: CFN), the San Diego-based medical technology company, said it has agreed to buy Intermed Equipamento Medico Hospitalar, a privately held respiratory equipment maker based in … Next Page »